BYFAVO

USDailyMed:Remimazolam N05CD14(WHO) CA:Schedule IVDE:Anlage III(Special prescription form required)UK:UnderPsychoactive Substances ActUS:Schedule IVEU:Rx-only methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate 308242-62-8Y 9867812 DB12404Y 8043503N 7V4A8U16MB D11788as salt:D10194 ChEMBL4297526 DTXSID20953024 Interactive image COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21 InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,1​​​‍​​‍​​​​‍​​‍‍0-12,17H,7,9H2,1-2H3/t17-/m0/s1NKey:CYHWMBVXXDIZNZ-KRWDZBQOSA-NN Remimazolam, sold under the brand nameByfavo, is amedicationfor the induction and maintenance ofprocedural sedationin adults for invasive diagnostic or surgical procedures lasting 30 minutes or less.It is abenzodiazepinedrug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepinemidazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and humanclinical trialsshowed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications. The most common side effects for procedural sedation includelow blood pressure,high blood pressure, diastolic hypertension,systolic hypertension,low blood oxygen level, and diastolic hypotension. Remimazolam was approved for medical use in the United States in July 2020,and in the European Union in March 2021.